Spergualin: a new antitumour antibiotic

Area of Science:

• Microbiology
• Pharmacology
• Immunology

Background:

• Spergualin is an antitumour substance isolated from Bacillus laterosporus.
• It exhibits a unique chemical structure and demonstrated chemotherapeutic potential.

Purpose of the Study:

• To evaluate the antitumour activity of spergualin against various mouse transplantable leukaemias.
• To investigate the mechanism of immunity induction and structure-activity relationships of spergualin.

Main Methods:

• Testing spergualin's efficacy on leukaemic mouse models (L-1210, P-388, P-815, C-1489, EL-4, RL male 1).
• Assessing the induction of specific immunity in cured mice.
• Analyzing the structure-activity relationship and the role of amine oxidase in its cytostatic effects.

Main Results:

• Spergualin showed significant chemotherapeutic effects, particularly against L-1210 leukaemia, with complete cures observed.
• Immunity induction was suggested in cured mice, potentially involving cytotoxic T lymphocytes.
• The spermidine moiety was essential for antitumour activity, while the 15-hydroxy group was not necessary.

Conclusions:

• Spergualin is a potent antitumour agent with curative potential for L-1210 leukaemia in mice.
• It can induce specific immunity, highlighting its potential in cancer immunotherapy.
• Structural modifications, such as 15-deoxy derivative, can enhance its antitumour potency.